NCT06533722CompletedPhase 2
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
A Phase II Study of the Efficacy and Safety of Adaptive Therapy for Metastatic Refractory Breast Cancer
Source: ClinicalTrials.gov · Last updated 10 Jun 2025
Brief summary (registry, in English)
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 30 Jul 2024
- Start date
- 4 Aug 2024
- Primary completion date
- 20 Sept 2024
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06533722
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 10
- From 4 Aug 2024 to the primary completion date, 20 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of any other anti-cancer therapy.
Other illness
- Evidence of active acute or chronic infection.
- Hepatic, renal, cardiac, or bone marrow dysfunction.
- Concurrent malignancy or history of other malignancy within the last five years.
Other
- Pregnant or breast feeding.
- Uncontrolled medical problems.
- Patients were unable or unwilling to comply with program requirements.
Who the study is looking for
- Understands and voluntarily signs the informed consent form.
- Minimum life expectancy 16 weeks.
- Histologically or cytologically confirmed advanced invasive breast cancer.
- Histological type: human epidermal growth factor receptor 2 (HER2) negative.
- Prior failure of at least first-line treatment for metastatic disease.
- At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- Adequate organ function including bone marrow, renal function, hepatic function, and cardiac reserve.
- Premenopausal women must use medically acceptable contraception during the study.
- Compliance with the study protocol.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.